Cytochrome P450IIE1 Genetic Polymorphisms, Racial Variation, and Lung Cancer Risk

Shunji Kato, Peter G. Shields, Neil E. Caporaso, Robert N. Hoover, Benjamin F. Trump, Haruhiko Sugimura, Ainsley Weston, and Curtis C. Harris

Laboratory of Human Carcinogenesis [K. K., R. G. S., A. W., C. C. H.] and Environmental Epidemiology Branch [N. E. C., R. N. H.], Division of Cancer Etiology, National Cancer Institute, NIH, Bethesda, Maryland 20892; Department of Pathology, University of Maryland, Baltimore, Maryland 21201 [B. F. T.]; and First Department of Pathology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan 431-31 [H. S.]

Abstract

Cytochrome P450IIE1 is responsible for the activation of carcinogenic N-nitrosamines, benzene, urethane, and other low-molecular-weight compounds. Restriction fragment length polymorphisms (PstI and RsaI restriction enzymes) have been identified in the cytochrome P450IIE1 transcription regulatory region that may affect expression. This study describes the PstI and RsaI polymorphisms in different racial populations and in a case-control study of lung cancer. The allelic frequencies were markedly different in Japanese, African-Americans, and Caucasians: the PstI rare allele was present at a frequency of 2% in Caucasians, 5% in African-Americans, and 24% in Japanese (P < 0.05). For the RsaI rare allele, frequencies were 2% in Caucasians, 2% in African-Americans, and 27% in Japanese (P < 0.05). The assay was also applied to 126 individuals enrolled in a case-control study of lung cancer. Although limited in statistical power, the data indicate no evidence for an association in the aggregate of cytochrome P450IIE1 polymorphisms with lung cancer in this U.S. population. When analyzed by race, the lung cancer odds ratio for the PstI mutant allele in African-Americans was 0.19 (95% C.I. = 0.03–1.38), and in Caucasians it was 4.13 (95% C.I. = 0.34–48.8). For the RsaI mutant allele, the odds ratios were 0.20 (95% C.I. = 0.02–2.43) and 4.28 (95% C.I. = 0.35–50.6), respectively. The ethnic differences of these restriction fragment length polymorphisms might be related to genetic susceptibilities for lung cancer among Caucasians and for gastric or esophageal cancer among Japanese.

Introduction

Molecular genetic techniques are useful for studying individual cancer risk because they can evaluate the ability to activate or eliminate carcinogens and repair DNA. Molecular epidemiology can relate such parameters to environmental carcinogen exposure, life style, occupation, and other inherited or acquired host factors (1). Most chemical carcinogens undergo metabolic activation, usually by CYP enzymes (2). More than 100 different human CYP enzymes have been identified or are assumed to exist (3); for many of these there is wide interindividual variation (4). CYP activity can be assessed by urinary phenotyping methods (e.g., CYP2D6; Refs. 5 and 6), adduct (7) or metabolite formation in cultured cells [e.g., aryl hydrocarbon hydroxylase (8) and glutathione transferase (9, 10)], or genotyping methods [e.g., CYP1A1 (11) and CYP2D6 (12)]. These methods, when applied in well-designed epidemiological studies of cancer, are useful for determining metabolic capacity and cancer risk.

CYP2E1 catalyzes oxidation and DNA adduct formation of many low-molecular-weight potential human carcinogens such as N-nitrosamines, aniline, vinyl chloride, and urethane (13, 14). Historically, CYP2E1 was characterized by its ethanol inducibility and metabolism of acetone and alcohols (13). N-Nitrosamines are ubiquitous in the environment, present in tobacco smoke, and formed endogenously in the stomach (15). They are potent carcinogens in laboratory animals (15, 16). Epidemiological studies also support a causal relationship of N-nitrosamine exposure to human cancers (16–21). Interindividual differences in CYP2E1 activity or induction may result from genetic susceptibility to these chemical carcinogens (13, 22).

Recently, two reports have described RFLPs of CYP2E1. The first, with either PstI or RsaI restriction sites, is located in the transcription regulation region of CYP2E1 (23). This set of polymorphisms, linked with each other, was associated with increased gene expression when a chloramphenicol acetyltransferase-containing construct was transfected into HepG2 cells and analyzed for chloramphenicol acetyltransferase activity (23). Specifically, the wild-type or more common allele had a lower expression rate compared to the mutant or less common allele. The other polymorphism, located in intron 6,3 is revealed using the DraI restriction enzyme (24). Although a direct relationship of this RFLP to CYP2E1 expression and activity has not been established, the distribution of the DraI genotypes in Japanese was different between lung cancer patients and controls (24). A relationship between the DraI and PstI or RsaI RFLP has not been reported. Moreover, the PstI and RsaI RFLPs have not yet been studied for lung cancer susceptibility.

Patients and Methods

Subjects. Octogenarian Japanese, Americans from a Baltimore autopsy donor program, and Americans enrolled in a Baltimore case-control study of lung cancer were analyzed for CYP2E1 PstI and RsaI genotypes. The case-control study design has been described in detail elsewhere (25). Briefly, cases were patients with histologically confirmed primary lung cancer. Two control groups were accrued. The first group consisted of patients with chronic obstructive pulmonary disease (defined as either abnormal pulmonary function tests or a history of greater than 40 pack-years of tobacco smoking). The second

Received 8/18/92; accepted 10/16/92.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom requests for reprints should be addressed, at Laboratory of Human Carcinogenesis, Division of Epiology, National Cancer Institute, NIH, Building 37, Room 2C16, Bethesda, MD 20892.

2 The abbreviations used are: CYP, cytochrome P450; RFLP, restriction fragment length polymorphism; C.I., confidence interval; PCR, polymerase chain reaction.

3 K. Watanabe, personal communication.
group consisted of patients with cancer at anatomical sites other than lung or bladder. The study design allowed for adjustment by age, gender, asbestos exposure, race, and tobacco use in the analysis. All study subjects completed a standardized questionnaire including demographic data, illness, family history, recent or remote diet, occupational history, and information about alcohol and tobacco consumption. A subset of subjects was selected from the original study based upon availability of DNA (128 from a total of 191 subjects).

**RLFP Analysis of CYP2E1.** DNA (peripheral blood buffy coat for case-control study subjects and Japanese; lung for autopsy donors) was isolated from tissues by phenol extraction methods as previously described (26). The PCR was used to amplify the transcription regulation region of CYP2E1 that includes the enzyme recognition sites for both PstI and RsaI (23). Genomic DNA (0.15 μg) was amplified with primers (0.8 μM) from locus -1370 to -1349 (5'-CCAGTCAGTGTTACATTGTC-3') and -999 to -978 (5'-TTCATTCTGTCTTTAAGCG-3') in buffer (10 mM tris-HCl, 50 mM KCl, 2 mM MgCl₂, pH 8.3) with 2'-deoxynucleotide-3'-triphosphates (1.875 mM; Pharmacia, Piscataway, NJ) and Taq polymerase (2.5 μl; Perkin Elmer, Norwalk, CT) to yield a 412-base pair fragment. The PCR product (15 μl) was subjected to PstI restriction enzyme digestion (10 units; New England Biolabs, Inc., Beverly, MA) in buffer (50 mM Tris-HCl, 50 mM NaCl, 10 mM MgCl₂, 1 mM dithiothreitol, pH 8.3, at 37°C for 18 h) or RsaI restriction enzyme digestion (5 units; New England Biolabs, Inc., Beverly, MA) in buffer (90 mM MgCl₂, 1 mM dithiothreitol at 37°C for 18 h). The samples were then analyzed by electrophoresis in agarose gel (2.2%).

**Table 1**

<table>
<thead>
<tr>
<th></th>
<th>No. of subjects</th>
<th>PstI</th>
<th>RsaI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Caucasians a,b</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>107</td>
<td>0.98 (210)²</td>
<td>0.02 (4)</td>
</tr>
<tr>
<td></td>
<td>African-Americans a,b</td>
<td>87</td>
<td>0.95 (165)</td>
</tr>
<tr>
<td></td>
<td>Japanese ²</td>
<td>49</td>
<td>0.76 (74)</td>
</tr>
</tbody>
</table>

a The allelic frequencies for PstI and RsaI RFLPs at the CYP2E1 locus are significantly different between Japanese and Caucasians (P < 0.05), and Japanese and African-Americans (P < 0.05), but not between Caucasians and African-Americans (P > 0.05) (Fisher's exact test).

b The allelic frequencies in Caucasians and African-Americans from autopsy samples are similar to those from the case-control study samples.

c Parentheses indicate number of alleles.

**Table 2**

<table>
<thead>
<tr>
<th>No. of subjects</th>
<th>Lung cancer cases</th>
<th>COPD a</th>
<th>Other cancer b</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>67</td>
<td>41</td>
<td>20</td>
</tr>
<tr>
<td>Mean age (years)</td>
<td>64</td>
<td>61</td>
<td>63</td>
</tr>
<tr>
<td>Pack-years c</td>
<td>59</td>
<td>67</td>
<td>47</td>
</tr>
<tr>
<td>Gender (male/female)</td>
<td>65/2</td>
<td>40/1</td>
<td>14/5</td>
</tr>
<tr>
<td>Caucasians (%)</td>
<td>47</td>
<td>56</td>
<td>40</td>
</tr>
</tbody>
</table>

a Chronic obstructive pulmonary disease.
b Subjects with cancer at anatomical sites other than the lung or urinary bladder.
c Average tobacco packs smoked per day multiplied by the number of years consumed.

**Results and Discussion**

Samples subjected to PCR and PstI or RsaI enzymatic digestion revealed predictable base-pair fragment lengths (Fig. 1). The PCR and PstI or RsaI restriction enzyme digests were applied to 194 U.S. and 49 Japanese individuals. The distribution of alleles in Caucasians, African-Americans, and Japanese is shown in Table 1 (23). The allelic frequencies in the Japanese samples were similar to those in a previous report (0.8 and 0.2 for wild type and mutant, respectively) (28). However, the allelic frequencies in Japanese were statistically different from Caucasians (P < 0.05) and African-Americans (P < 0.05), but there was no significant difference between U.S. Caucasians and African-Americans. The allelic frequencies among autopsies and case-control study samples were similar. In all groups (by race and diagnosis), the allelic frequencies met Hardy-Weinberg equilibrium. As previously reported (23), the PstI and RsaI genotypes were generally linked, although eight cases were identified where there was no concordance. All were heterozygotes for the PstI allele, 6 were in African-Americans, and 2 were in Japanese. Interestingly, as predicted from the allelic frequencies of the groups, these haplotypes appear to be race-specific among Japanese and African-Americans. In the PstI RFLP heterozygotes, the 6 African-Americans were all RsaI homozygous wild type, while the two Japanese were RsaI homozygous mutants. This likely represents the temporal relationship for the establishment of the mutation in each population.

Table 2 reports the characteristics of the case-control study subjects. The frequency of genotypes was the same for the cases and controls, whether examined by PstI (Table 3) or RsaI (data not shown). There was no unique grouping by lung cancer histological type or smoking status. The results of this analysis would suggest therefore that there is no association of the CYP2E1 genotypes with lung cancer risk. It should be noted that due to the low incidence of heterozygotes and absence of
homoygotes, the statistical power of the study is severely limited. In this case, if we assumed an odds ratio of 2 (risk of disease in individuals with one mutant allele compared to those without), the power would be only 0.30; over 600 subjects would be needed to achieve a power of 0.80. In the Japanese population, study size of less than 250 subjects would be adequate.

The crude odds ratio for lung cancer risk in the aggregate data was 0.7 (95% C.I. = 0.2–5.4) for PstI and 0.9 (95% C.I. = 0.2–2.8) for RsaI. The odds ratios for lung cancer risk having at least one PstI mutant allele in African-Americans was 0.19 (95% C.I. = 0.03–1.38; $\chi^2 = 2.50; P = 0.11$) and in Caucasians was 4.13 (95% C.I. = 0.34–48.8; $\chi^2 = 2.0; P = 0.16$). For RsaI mutant alleles, the odds ratios were 0.20 (95% C.I. = 0.02–2.43; $\chi^2 = 1.24; P = 0.26$) and 4.28 (95% C.I. = 0.35–50.6; $\chi^2 = 2.0; P = 0.16$), respectively. Thus, future studies need to determine risks separately by race.

Although a larger study size will be required to definitively test this association, these RFLPs are unlikely to be a common lung cancer risk factor in U.S. populations. The lung cancer rates in male Japanese, U.S. Caucasians, and U.S. African-Americans are 28, 79, and 110 per 100,000, respectively (29, 30), which are inversely (Japanese and U.S. in aggregate) related to the presence of the rare allele, suggesting a limited role, if any, in lung cancer risk. However, the marked difference in allelic frequency between Japanese and U.S. individuals might be important for the risk of gastric and esophageal cancer. The rate in Japanese males for esophageal cancer is almost twice that in U.S. Americans and for gastric cancer is almost eight times (29, 30). The association of these tumors with CYP2E1 genotypes and transcription worthy of study. Differences in CYP2E1 allelic frequencies also are reminiscent of findings for differences in ethanol sensitivity for Orientals and Caucasians (31) as well as for racial differences in alcohol dehydrogenase (32). These relationships need to be further explored.

Acknowledgments

The authors wish to thank Elise D. Bowman for technical assistance and Drs. Shoichiro Tsugame and Kohichiro Ohtsubo for preparing DNA samples. We are grateful to Dr. M. Watanabe for the personal communication. We also thank Dorothea Dudek for her skillful editorial assistance with the preparation of the manuscript.

References

25. Caporaso, N. E., Tucker, M. A., Hoover, R., Hayes, R. B., Pickle, L. W.,


Cytochrome P450IIE1 Genetic Polymorphisms, Racial Variation, and Lung Cancer Risk


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/52/23/6712

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.